Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 2/20 | 0.45 |
| ▸ | KIT | P10721 | 2/20 | 0.45 |
| ▸ | FLT1 | P17948 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | ABL2 | P42684 | 2/20 | 0.45 |
| ▸ | FLT4 | P35916 | 1/20 | 0.45 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | F10 | P00742 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375160 | 1.00 | ADH1A (0.45) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL31413354 | 1.00 | ADH1A (0.45) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL13293994 | 1.00 | ADH1A (0.45) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL31413355 | 1.00 | ADH1A (0.45) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL9885494 | 1.00 | ADH1A (0.45) | ADH1AKITFLT1KDRABL2 | |
| Hydrochloric Acid SCHEMBL30944523 | 0.98 | ADH1A (0.44) | ADH1AKITFLT1KDRABL2 | |
| Hydrochloric Acid SCHEMBL16933151 | 0.98 | ADH1A (0.44) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL13564476 | 0.85 | ADH1A (0.34) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL13564469 | 0.85 | ADH1A (0.34) | ADH1AKITFLT1KDRABL2 | |
| SCHEMBL14527500 | 0.85 | ADH1A (0.34) | ADH1AKITFLT1KDRABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109789158-B | RUNX inhibitors | 国立大学法人京都大学 | 2022-06-03 | — | — | CN | claimed |
| US-11235001-B2 | RUNX inhibitor | KYOTO UNIVERSITY (JP) | 2022-02-01 | — | — | US | claimed |
| US-20190247425-A1 | RUNX INHIBITOR | KYOTO UNIVERSITY (JP) | 2019-08-15 | — | — | US | claimed |
| EP-3492087-A1 | RUNX INHIBITOR | Kyoto University (JP) | 2019-06-05 | — | — | EP | claimed |
| WO-2015038426-A1 | SELF-IMMOLATIVE LINKERS CONTAINING MANDELIC ACID DERIVATIVES, DRUG-LIGAND CONJUGATES FOR TARGETED THERAPIES AND USES THEREOF | ASANA BIOSCIENCES, LLC (US) | 2015-03-19 | — | — | WO | claimed |
| EP-2044436-B1 | METHODS AND COMPOSITIONS FOR DETECTION OF MICROORGANISMS AND CELLS AND TREATMENT OF DISEASES AND DISORDERS | GENELUX CORP (US) | 2014-06-04 | — | — | EP | claimed |
| EP-2028270-B9 | Modified recombinant vaccinia viruses, uses thereof | GENELUX CORP (US) | 2012-04-25 | — | — | EP | claimed |
| EP-2028270-B1 | Modified recombinant vaccinia viruses, uses thereof | GENELUX CORP (US) | 2012-02-15 | — | — | EP | claimed |
| EP-1644492-B1 | MODIFIED RECOMBINANT VACCINIA VIRUSES, USES THEREOF | GENELUX CORP (US) | 2009-01-07 | — | — | EP | claimed |
| US-20260137773-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | VIROMISSILE, INC. (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260102417-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CANCER | KEYZELL HOLDING S L (ES) | 2026-04-16 | — | — | US | disclosed |
| EP-4208564-B1 | NUCLEIC ACID MODIFYING REAGENTS AND USES THEREOF | PROMEGA CORP (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12571031-B2 | Nucleic acid modifying reagents and uses thereof | PROMEGA CORPORATION (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | PHEON THERAPEUTICS LTD (GB) | 2026-01-29 | — | — | US | disclosed |
| WO-2007038658-A2 | ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | MEDAREX, INC. (US) | 2007-04-05 | — | — | WO | disclosed |
| EP-1731519-A1 | NOVEL INDOLE DERIVATIVE FOR ALKYLATING SPECIFIC BASE SEQUENCE OF DNA AND ALKYLATING AGENT AND DRUG EACH COMPRISING THE SAME | TMRC Co., Ltd. (JP) | 2006-12-13 | — | — | EP | disclosed |
| EP-1644492-A2 | MODIFIED RECOMBINANT VACCINIA VIRUSES AND OTHER MICROORGANISMS, USES THEREOF | Genelux Corporation (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1320522-B1 | COMPOSITIONS AND METHODS OF THE USE THEREOF ACHIRAL ANALOGUES OF CC-1065 AND THE DUOCARMYCINS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005047458-A2 | MODIFIED RECOMBINANT VACCINA VIRUSES AND OTHER MICROORGANISMS, USES THEREOF | GENELUX CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| US-6559125-B1 | Alkylator linked to a polyamide, wherein polyamide comprises at least one pyrrole or imidazole amino acid and wherein polyamide comprises a gamma-aminobutyric acid linked to alkylator; alkylator selectively alkylates one strand of DNA | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2003-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102417-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF CANCER | TACR1, TACR2, NPSR1 | ADH1A 1497/4885KIT 34/4885FLT1 929/4885 |
| US-20260137773-A1 | ONCOLYTIC VACCINIA VIRUSES AND RECOMBINANT VIRUSES AND METHODS OF USE THEREOF | CASP9, TP53, CASP2 | ADH1A 4556/4885KIT 4229/4885FLT1 840/4885 |
| US-20190247425-A1 | RUNX INHIBITOR | RUNX1, MLX, CBX2 | ADH1A 3636/4885KIT 34/4885FLT1 2171/4885 |
| US-11235001-B2 | RUNX inhibitor | RUNX1, MLX, CBX2 | ADH1A 3636/4885KIT 34/4885FLT1 2171/4885 |
| US-20260027226-A1 | ANTIBODY-DRUG CONJUGATES | SLC3A2, MTCL3, SLC13A2 | ADH1A 1023/4885KIT 3669/4885FLT1 281/4885 |
| US-12571031-B2 | Nucleic acid modifying reagents and uses thereof | POLRMT, ADAR, NCL | ADH1A 2607/4885KIT 2505/4885FLT1 3821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.